(NASDAQ:MITO) – Shares are moving this morning up more than 45% on news of positive Phase 1 study results showing upper neuron improvement and safety.
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium
SBT-272 improved neuronal health, superior to other approved and investigational agents
Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway Stealth BioTherapeutics Corp a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology, which plays a significant role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data were presented at the Keystone Neurodegeneration Symposium in Keystone, CO held June 5-9,2022. A Phase 1 study to evaluate the safety and tolerability of SBT-272 in healthy volunteers is underway.